Menu Search
Equities

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

ONCSM.E:IST

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS

Actions
Health CareMedical Equipment and Services
  • Price (TRY)141.80
  • Today's Change-3.00 / -2.07%
  • Shares traded6.08m
  • 1 Year change-29.80%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 16:09 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in TRYIncome statement in TRYView more

Year on year Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS's revenues fell -17.90% from 292.94m to 240.51m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 20.76m to a larger loss of 79.81m.
Gross margin12.64%
Net profit margin-44.11%
Operating margin-31.81%
Return on assets-39.93%
Return on equity-58.76%
Return on investment-55.93%
More ▼

Cash flow in TRYView more

In 2023, Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS increased its cash reserves by 204.11%, or 39.29m. Cash Flow from Financing totalled 118.31m or 49.19% of revenues. In addition the company used 57.33m for operations while cash used for investing totalled 21.69m.
Cash flow per share-2.98
Price/Cash flow per share--
Book value per share9.56
Tangible book value per share9.34
More ▼

Balance sheet in TRYView more

Oncosem Onkolojik Sistemler Sanayi ve Ticaret AS has a Debt to Total Capital ratio of 23.56%, a higher figure than the previous year's 1.02%.
Current ratio1.81
Quick ratio1.06
Total debt/total equity0.3082
Total debt/total capital0.2356
More ▼

Growth rates in TRY

Year on year, growth in earnings per share excluding extraordinary items dropped -287.01%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-301.54
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.